SCHEMBL8970336

SCHEMBL8970336

COc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 5/20 0.58
ADORA3 P0DMS8 4/20 0.56
ADORA1 P30542 3/20 0.56
ADORA2A P29274 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
DPP4 P27487 1/20 0.56
MEN1 O00255 1/20 0.56
SLC28A1 O00337 1/20 0.56
MAP3K7 O43318 1/20 0.56
SLC28A2 O43868 1/20 0.56
GAPDH P04406 1/20 0.56
MAPK1 P28482 1/20 0.56
ADORA2B P29275 1/20 0.56
STAT6 P42226 1/20 0.56
PI4KA P42356 1/20 0.56
KMT2A Q03164 1/20 0.56
PI4K2B Q8TCG2 1/20 0.56
DOT1L Q8TEK3 1/20 0.56
PI4K2A Q9BTU6 1/20 0.56
SLC28A3 Q9HAS3 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12552334 1.00 SLC29A1 (0.58) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL8970347 1.00 SLC29A1 (0.58) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL8971479 0.90 SLC29A1 (0.59) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL8971495 0.90 SLC29A1 (0.59) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL6887353 0.90 SLC29A1 (0.70) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL1979130 0.90 SLC29A1 (0.70) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL9142042 0.90 SLC29A1 (0.70) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL4081006 0.90 SLC29A1 (0.70) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL6903709 0.90 SLC29A1 (0.70) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2
SCHEMBL24443663 0.85 SLC29A1 (0.57) SLC29A1ADORA3ADORA1ADORA2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0417999-B1 Antiviral compounds WELLCOME FOUND (GB) 1996-03-13 EP disclosed
EP-0671410-A1 Antiviral compounds THE WELLCOME FOUNDATION LIMITED (GB) 1995-09-13 EP disclosed
US-5420115-A Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides BURROUGHS WELLCOME CO. (US) 1995-05-30 US disclosed
EP-0428109-A2 Deoxyfluoronucleoside process Bristol-Myers Squibb Company (US) 1991-05-22 EP disclosed
EP-0417999-A1 Antiviral compounds THE WELLCOME FOUNDATION LIMITED (GB) 1991-03-20 EP disclosed